Followers | 519 |
Posts | 67213 |
Boards Moderated | 1 |
Alias Born | 06/10/2009 |
Wednesday, March 01, 2023 9:39:35 AM
Under the terms of the letter of intent, Clearday’s existing equity holders would convert 100% of their equity into the combined public company. The proposed transaction values Clearday at $250 million. Viveon expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed.
Completion of a business combination with Clearday is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and stockholders of both Viveon and Clearday. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all.
Recent CLRD News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:35:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:19:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:00:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:45:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:15:22 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 10/31/2023 08:42:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 08:30:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/14/2023 10:06:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 03:00:11 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:31:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/18/2023 08:47:16 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM